SOMERSET, NJ/August 22/PRNewswire-First Call/--Alfacell Corporation announced the findings of a paper published in the International Journal of Oncology (2007; Vol. 31, Issue 3: 663-669) which reported that treatment with the cancer drug ONCONASE (R) substantially decreases intracellular oxidative stress by suppressing reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. ONCONASE is a first-in-class product based of Alfacell's proprietary ribonclease (RNase) technology. Derived from a natural protein isolated from the leopard frog, ONCONASE has been shown in labratory and clinical tests to target cancer cells while sparing normal cells.

Click here to view the full announcement.